Abstract
Reactivation of latent VZV remains a significant cause of morbidity after SCT. Twenty-five percent or more of patients undergoing SCT will experience zoster within the first year after transplant. Short-course (<1 year) prophylaxis with acyclovir has been shown to be effective, but compliance with five times daily dosing may be problematic. We conducted a randomized, double-blind, placebo-controlled trial of valacyclovir (VACV) 1000 mg twice daily from 4 through 24 months after SCT for the prevention of VZV. Fifty-three VZV-seropositive transplant recipients (17 auto-SCT, 36 allo-SCT) were randomized at a median of 163 days after SCT. In a modified intent-to-treat analysis of 49 patients who took study drug, 0 of 22 in the VACV arm experienced zoster reactivation, compared with 6 of 26 (23%) in the placebo arm (P=0.025). Thirty-two subjects completed therapy through the second year post transplant or first episode of zoster. Adverse events resulting in discontinuation were more frequent in the placebo group (5 of 26 vs 3 of 27 for placebo and study drug, respectively). VACV at a dose of 1000 mg twice daily through 24 months after transplant is well tolerated and effective in suppressing shingles after SCT.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Arvin AM . Varicella-zoster virus: pathogenesis, immunity, and clinical management in hematopoietic cell transplant recipients. Biol Blood Marrow Transplant 2000; 6: 219–230.
Cohen JI, Brunell PA, Straus SE, Krause PR . Recent advances in varicella-zoster virus infection. Ann Intern Med 1999; 130: 922–932.
Ku CC, Besser J, Abendroth A, Grose C, Arvin AM . Varicella-zoster virus pathogenesis and immunobiology: new concepts emerging from investigations with the SCIDhu mouse model. J Virol 2005; 79: 2651–2658.
Levin MJ, Hayward AR . The varicella vaccine. Prevention of herpes zoster. Infect Dis Clin North Am 1996; 10: 657–675.
Boeckh M, Kim HW, Flowers ME, Meyers JD, Bowden RA . Long-term acyclovir for prevention of varicella zoster virus disease after allogeneic hematopoietic cell transplantation--a randomized double-blind placebo-controlled study. Blood 2006; 107: 1800–1805.
Erard V, Guthrie KA, Varley C, Heugel J, Wald A, Flowers ME et al. One-year acyclovir prophylaxis for preventing varicella-zoster virus disease after hematopoietic cell transplantation: no evidence of rebound varicella-zoster virus disease after drug discontinuation. Blood 2007; 110: 3071–3077.
Kanda Y, Mineishi S, Saito T, Saito A, Yamada S, Ohnishi M et al. Long-term low-dose acyclovir against varicella-zoster virus reactivation after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2001; 28: 689–692.
Kim DH, Messner H, Minden M, Gupta V, Kuruvilla J, Wright J et al. Factors influencing varicella zoster virus infection after allogeneic peripheral blood stem cell transplantation: low-dose acyclovir prophylaxis and pre-transplant diagnosis of lymphoproliferative disorders. Transpl Infect Dis 2008; 10: 90–98.
Ljungman P, Wilczek H, Gahrton G, Gustavsson A, Lundgren G, Lonnqvist B et al. Long-term acyclovir prophylaxis in bone marrow transplant recipients and lymphocyte proliferation responses to herpes virus antigens in vitro. Bone Marrow Transplant 1986; 1: 185–192.
Perren TJ, Powles RL, Easton D, Stolle K, Selby PJ . Prevention of herpes zoster in patients by long-term oral acyclovir after allogeneic bone marrow transplantation. Am J Med 1988; 85: 99–101.
Sempere A, Sanz GF, Senent L, de la RJ, Jarque I, Lopez F et al. Long-term acyclovir prophylaxis for prevention of varicella zoster virus infection after autologous blood stem cell transplantation in patients with acute leukemia. Bone Marrow Transplant 1992; 10: 495–498.
Steer CB, Szer J, Sasadeusz J, Matthews JP, Beresford JA, Grigg A . Varicella-zoster infection after allogeneic bone marrow transplantation: incidence, risk factors and prevention with low-dose aciclovir and ganciclovir. Bone Marrow Transplant 2000; 25: 657–664.
Thomson KJ, Hart DP, Banerjee L, Ward KN, Peggs KS, Mackinnon S . The effect of low-dose aciclovir on reactivation of varicella zoster virus after allogeneic haemopoietic stem cell transplantation. Bone Marrow Transplant 2005; 35: 1065–1069.
Brigden D, Fiddian P, Rosling AE, Ravenscroft T . Acyclovir—a review of the preclinical and early clinical data of a new antiherpes drug. Antiviral Res 1981; 1: 203–212.
Balfour Jr HH, McMonigal KA, Bean B . Acyclovir therapy of varicella-zoster virus infections in immunocompromised patients. J Antimicrob Chemother 1983; 12 (Suppl B): 169–179.
Serota FT, Starr SE, Bryan CK, Koch PA, Plotkin SA, August CS . Acyclovir treatment of herpes zoster infections. Use in children undergoing bone marrow transplantation. JAMA 1982; 247: 2132–2135.
Wade JC, Newton B, McLaren C, Flournoy N, Keeney RE, Meyers JD . Intravenous acyclovir to treat mucocutaneous herpes simplex virus infection after marrow transplantation: a double-blind trial. Ann Intern Med 1982; 96: 265–269.
Balfour Jr HH, Bean B, Laskin OL, Ambinder RF, Meyers JD, Wade JC et al. Acyclovir halts progression of herpes zoster in immunocompromised patients. N Engl J Med 1983; 308: 1448–1453.
Beutner KR . Valacyclovir: a review of its antiviral activity, pharmacokinetic properties, and clinical efficacy. Antiviral Res 1995; 28: 281–290.
Jacobson MA . Valaciclovir (BW256U87): the L-valyl ester of acyclovir. J Med Virol 1993: (Suppl 1): 150–153.
Koc Y, Miller KB, Schenkein DP, Griffith J, Akhtar M, DesJardin J et al. Varicella zoster virus infections following allogeneic bone marrow transplantation: frequency, risk factors, and clinical outcome. Biol Blood Marrow Transplant 2000; 6: 44–49.
Christiansen NP, Haake RJ, Hurd DD . Early herpes zoster infection in adult patients with Hodgkin's disease undergoing autologous bone marrow transplant. Bone Marrow Transplant 1991; 7: 435–437.
Han CS, Miller W, Haake R, Weisdorf D . Varicella zoster infection after bone marrow transplantation: incidence, risk factors and complications. Bone Marrow Transplant 1994; 13: 277–283.
Ljungman P, Lonnqvist B, Gahrton G, Ringden O, Sundqvist VA, Wahren B . Clinical and subclinical reactivations of varicella-zoster virus in immunocompromised patients. J Infect Dis 1986; 153: 840–847.
Locksley RM, Flournoy N, Sullivan KM, Meyers JD . Infection with varicella-zoster virus after marrow transplantation. J Infect Dis 1985; 152: 1172–1181.
Schuchter LM, Wingard JR, Piantadosi S, Burns WH, Santos GW, Saral R . Herpes zoster infection after autologous bone marrow transplantation. Blood 1989; 74: 1424–1427.
Arora A, Mendoza N, Brantley J, Yates B, Dix L, Tyring S . Double-blind study comparing 2 dosages of valacyclovir hydrochloride for the treatment of uncomplicated herpes zoster in immunocompromised patients 18 years of age and older. J Infect Dis 2008; 197: 1289–1295.
Jacobson MA, Gallant J, Wang LH, Coakley D, Weller S, Gary D et al. Phase I trial of valaciclovir, the L-valyl ester of acyclovir, in patients with advanced human immunodeficiency virus disease. Antimicrob Agents Chemother 1994; 38: 1534–1540.
Madkan VK, Arora A, Babb-Tarbox M, Aboutlabeti S, Tyring S . Open-label study of valacyclovir 1.5 g twice daily for the treatment of uncomplicated herpes zoster in immunocompetent patients 18 years of age or older. J Cutan Med Surg 2007; 11: 89–98.
Tyring SK, Beutner KR, Tucker BA, Anderson WC, Crooks RJ . Antiviral therapy for herpes zoster: randomized, controlled clinical trial of valacyclovir and famciclovir therapy in immunocompetent patients 50 years and older. Arch Fam Med 2000; 9: 863–869.
Ljungman P, de la CR, Milpied N, Volin L, Russell CA, Crisp A et al. Randomized study of valacyclovir as prophylaxis against cytomegalovirus reactivation in recipients of allogeneic bone marrow transplants. Blood 2002; 99: 3050–3056.
Prentice HG, Gluckman E, Powles RL, Ljungman P, Milpied N, Fernandez Ranada JM et al. Impact of long-term acyclovir on cytomegalovirus infection and survival after allogeneic bone marrow transplantation. European Acyclovir for CMV Prophylaxis Study Group. Lancet 1994; 343: 749–753.
Sano-Mori Y, Kanda Y, Oshima K, Kako S, Shinohara A, Nakasone H et al. Long-term ultra-low-dose acyclovir against varicella-zoster virus reactivation after allogeneic hematopoietic stem cell transplantation. Am J Hematol 2008; 83: 472–476.
Dykewicz CA, Kaplan JE, Jaffe HW, for the Centres for Disease Control and Prevention. Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. MMWR Recomm Rep 2000; 49 (RR-10): 1–7.
Acknowledgements
This study was supported in part by an unrestricted grant from GlaxoSmithKline. We would like to acknowledge the help of study coordinators Krista Garrison, MPH, Serena Louden, RN and Laurie Barefoot, RN. We would also like to thank Ms Robin Ruthazer, MPH for statistical assistance.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Klein, A., Miller, K., Sprague, K. et al. A randomized, double-blind, placebo-controlled trial of valacyclovir prophylaxis to prevent zoster recurrence from months 4 to 24 after BMT. Bone Marrow Transplant 46, 294–299 (2011). https://doi.org/10.1038/bmt.2010.99
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/bmt.2010.99
Keywords
This article is cited by
-
Acute graft-versus-host disease
Nature Reviews Disease Primers (2023)
-
Viral Hypothesis and Antiviral Treatment in Alzheimer’s Disease
Current Neurology and Neuroscience Reports (2018)
-
Varicella zoster virus infection
Nature Reviews Disease Primers (2015)
-
Diagnosis and treatment of viral diseases in recipients of allogeneic hematopoietic stem cell transplantation
Journal of Hematology & Oncology (2013)